DOI: 10.1016/j.ejca.2011.06.002. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

10.1016/j.ejca.2011.06.002

Crossref journal-article

Elsevier BV

European Journal of Cancer (78)

Bibliography

Thuss-Patience, P. C., Kretzschmar, A., Bichev, D., Deist, T., Hinke, A., Breithaupt, K., Dogan, Y., Gebauer, B., Schumacher, G., & Reichardt, P. (2011). Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer â A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer, 47(15), 2306â2314.

Authors 10

Peter C. Thuss-Patience (first)
Albrecht Kretzschmar (additional)
Dmitry Bichev (additional)
Tillman Deist (additional)
Axel Hinke (additional)
Kirstin Breithaupt (additional)
Yasemin Dogan (additional)
Bernhard Gebauer (additional)
Guido Schumacher (additional)
Peter Reichardt (additional)

References 29 Referenced 467

10.1200/JCO.2005.05.2308 / J Clin Oncol / Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world by Kamangar (2006)
10.3322/canjclin.49.1.33 / CA Cancer J Clin / Global Cancer Statistics by Parkin (1999)
10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P / Cancer / Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer by Murad (1993)
10.1038/bjc.1995.114 / Br J Cancer / Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer by Pyrhonen (1995)
Scheithauer W, Kornek G, Zeh B. Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer: a randomized trial. In: Second International Conference on Biology, Prevention, and Treatment of GI Malignancy, Köln, Germany; 1995. p. 68.
10.1023/A:1008243606668 / Ann Oncol / Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer by Glimelius (1997)
10.1056/NEJMoa073149 / N Engl J Med / Capecitabine and oxaliplatin for advanced esophagogastric cancer by Cunningham (2008)
10.1200/jco.2009.27.18_suppl.lba4509 / J Clin Oncol / Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) by Van Cutsem (2009)
10.1016/S1470-2045(08)70035-4 / Lancet Oncol / S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial by Koizumi (2008)
10.1177/030089160308900411 / Tumori / Single-agent irinotecan as second-line treatment for advanced gastric cancer by Kanat (2003)
10.1093/jjco/hyh006 / Jpn J Clin Oncol / Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy by Chun (2004)
10.1093/annonc/mdh007 / Ann Oncol / Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma by Assersohn (2004)
10.1038/sj.bjc.6602575 / Br J Cancer / Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer by Kim (2005)
{'key': '10.1016/j.ejca.2011.06.002_b0070', 'first-page': '4219', 'article-title': 'Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.)', 'volume': '23', 'author': 'Giuliani', 'year': '2003', 'journal-title': 'Anticancer Res'} / Anticancer Res / Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.) by Giuliani (2003)
{'key': '10.1016/j.ejca.2011.06.002_b0075', 'first-page': '2973', 'article-title': 'Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma', 'volume': '25', 'author': 'Kunisaki', 'year': '2005', 'journal-title': 'Anticancer Res'} / Anticancer Res / Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma by Kunisaki (2005)
10.1159/000087136 / Onkologie / Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy by Stahl (2005)
10.1016/j.clon.2004.10.006 / Clin Oncol (R Coll Radiol) / Review of second-line chemotherapy for advanced gastric adenocarcinoma by Wilson (2005)
10.1038/sj.bjc.6601226 / Br J Cancer / Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial by Köhne (2003)
10.1093/annonc/mdn166 / Ann Oncol / Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naïve patients with advanced adenocarcinoma of the stomach or osophagogastric junction by Dank (2008)
10.1200/JCO.2004.01.140 / J Clin Oncol by Bouche (2004)
10.1200/JCO.2003.08.058 / J Clin Oncol / Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer by Fuchs (2003)
10.1038/sj.bjc.6602462 / Br J Cancer / Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study by Van Cutsem (2005)
10.2307/2531201 / Biometrics / Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance and stratification by Lachin (1986)
10.1080/01621459.1958.10501452 / J Am Stat Ass / Nonparametric estimation from incomplete observations by Kaplan (1958)
{'key': '10.1016/j.ejca.2011.06.002_b0125', 'first-page': '185', 'article-title': 'Asymptotically efficient rank invariation test procedures (with discussion)', 'volume': '135', 'author': 'Peto', 'year': '1972', 'journal-title': 'J R Stat Soc'} / J R Stat Soc / Asymptotically efficient rank invariation test procedures (with discussion) by Peto (1972)
{'year': '1979', 'series-title': 'WHO Handbook for Reporting Results of Cancer Treatment, WHO Offset Publication No. 48', 'key': '10.1016/j.ejca.2011.06.002_b0165'} / WHO Handbook for Reporting Results of Cancer Treatment, WHO Offset Publication No. 48 (1979)
10.1200/jco.2010.28.18_suppl.lba4007 / J Clin Oncol / AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine, cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC) by Kang (2010)
10.1038/sj.bjc.6604732 / Br J Cancer / Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? by Catalano (2008)
10.1016/S1470-2045(09)70136-6 / Lancet Oncol / Is there a role for second-line chemotherapy in advanced gastric cancer? by Wesolowski (2009)

Dates

Type	When
Created	14 years, 1 month ago (July 12, 2011, 8:33 p.m.)
Deposited	6 years, 2 months ago (June 12, 2019, 6:58 p.m.)
Indexed	23 hours, 32 minutes ago (Aug. 31, 2025, 6:32 a.m.)
Issued	13 years, 11 months ago (Oct. 1, 2011)
Published	13 years, 11 months ago (Oct. 1, 2011)
Published Print	13 years, 11 months ago (Oct. 1, 2011)

Funders 0

None

BibTeX

@article{Thuss_Patience_2011, title={Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)}, volume={47}, ISSN={0959-8049}, url={http://dx.doi.org/10.1016/j.ejca.2011.06.002}, DOI={10.1016/j.ejca.2011.06.002}, number={15}, journal={European Journal of Cancer}, publisher={Elsevier BV}, author={Thuss-Patience, Peter C. and Kretzschmar, Albrecht and Bichev, Dmitry and Deist, Tillman and Hinke, Axel and Breithaupt, Kirstin and Dogan, Yasemin and Gebauer, Bernhard and Schumacher, Guido and Reichardt, Peter}, year={2011}, month=oct, pages={2306–2314} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2025,
        8,
        31
      ]
    ],
    "date-time": "2025-08-31T10:32:45Z",
    "timestamp": 1756636365620
  },
  "reference-count": 29,
  "publisher": "Elsevier BV",
  "issue": "15",
  "license": [
    {
      "start": {
        "date-parts": [
          [
            2011,
            10,
            1
          ]
        ],
        "date-time": "2011-10-01T00:00:00Z",
        "timestamp": 1317427200000
      },
      "content-version": "tdm",
      "delay-in-days": 0,
      "URL": "https://www.elsevier.com/tdm/userlicense/1.0/"
    }
  ],
  "content-domain": {
    "domain": [],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2011,
        10
      ]
    ]
  },
  "DOI": "10.1016/j.ejca.2011.06.002",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2011,
        7,
        13
      ]
    ],
    "date-time": "2011-07-13T00:33:47Z",
    "timestamp": 1310517227000
  },
  "page": "2306-2314",
  "source": "Crossref",
  "is-referenced-by-count": 467,
  "title": "Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer \u2013 A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)",
  "prefix": "10.1016",
  "volume": "47",
  "clinical-trial-number": [
    {
      "clinical-trial-number": "nct00144378",
      "registry": "10.18810/clinical-trials-gov"
    }
  ],
  "author": [
    {
      "given": "Peter C.",
      "family": "Thuss-Patience",
      "sequence": "first",
      "affiliation": []
    },
    {
      "given": "Albrecht",
      "family": "Kretzschmar",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Dmitry",
      "family": "Bichev",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Tillman",
      "family": "Deist",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Axel",
      "family": "Hinke",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Kirstin",
      "family": "Breithaupt",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Yasemin",
      "family": "Dogan",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Bernhard",
      "family": "Gebauer",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Guido",
      "family": "Schumacher",
      "sequence": "additional",
      "affiliation": []
    },
    {
      "given": "Peter",
      "family": "Reichardt",
      "sequence": "additional",
      "affiliation": []
    }
  ],
  "member": "78",
  "reference": [
    {
      "issue": "14",
      "key": "10.1016/j.ejca.2011.06.002_b0005",
      "doi-asserted-by": "crossref",
      "first-page": "2137",
      "DOI": "10.1200/JCO.2005.05.2308",
      "article-title": "Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world",
      "volume": "24",
      "author": "Kamangar",
      "year": "2006",
      "journal-title": "J Clin Oncol"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0010",
      "doi-asserted-by": "crossref",
      "first-page": "33",
      "DOI": "10.3322/canjclin.49.1.33",
      "article-title": "Global Cancer Statistics",
      "volume": "49",
      "author": "Parkin",
      "year": "1999",
      "journal-title": "CA Cancer J Clin"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0015",
      "doi-asserted-by": "crossref",
      "first-page": "37",
      "DOI": "10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P",
      "article-title": "Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer",
      "volume": "72",
      "author": "Murad",
      "year": "1993",
      "journal-title": "Cancer"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0020",
      "doi-asserted-by": "crossref",
      "first-page": "587",
      "DOI": "10.1038/bjc.1995.114",
      "article-title": "Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer",
      "volume": "71",
      "author": "Pyrhonen",
      "year": "1995",
      "journal-title": "Br J Cancer"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0025",
      "unstructured": "Scheithauer W, Kornek G, Zeh B. Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer: a randomized trial. In: Second International Conference on Biology, Prevention, and Treatment of GI Malignancy, K\u00f6ln, Germany; 1995. p. 68."
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0030",
      "doi-asserted-by": "crossref",
      "first-page": "163",
      "DOI": "10.1023/A:1008243606668",
      "article-title": "Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer",
      "volume": "8",
      "author": "Glimelius",
      "year": "1997",
      "journal-title": "Ann Oncol"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0035",
      "doi-asserted-by": "crossref",
      "first-page": "36",
      "DOI": "10.1056/NEJMoa073149",
      "article-title": "Capecitabine and oxaliplatin for advanced esophagogastric cancer",
      "volume": "358",
      "author": "Cunningham",
      "year": "2008",
      "journal-title": "N Engl J Med"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0040",
      "doi-asserted-by": "crossref",
      "first-page": "18s",
      "DOI": "10.1200/jco.2009.27.18_suppl.lba4509",
      "article-title": "Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)",
      "volume": "27",
      "author": "Van Cutsem",
      "year": "2009",
      "journal-title": "J Clin Oncol"
    },
    {
      "issue": "3",
      "key": "10.1016/j.ejca.2011.06.002_b0045",
      "doi-asserted-by": "crossref",
      "first-page": "215",
      "DOI": "10.1016/S1470-2045(08)70035-4",
      "article-title": "S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial",
      "volume": "9",
      "author": "Koizumi",
      "year": "2008",
      "journal-title": "Lancet Oncol"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0050",
      "doi-asserted-by": "crossref",
      "first-page": "405",
      "DOI": "10.1177/030089160308900411",
      "article-title": "Single-agent irinotecan as second-line treatment for advanced gastric cancer",
      "volume": "89",
      "author": "Kanat",
      "year": "2003",
      "journal-title": "Tumori"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0150",
      "doi-asserted-by": "crossref",
      "first-page": "8",
      "DOI": "10.1093/jjco/hyh006",
      "article-title": "Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy",
      "volume": "34",
      "author": "Chun",
      "year": "2004",
      "journal-title": "Jpn J Clin Oncol"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0060",
      "doi-asserted-by": "crossref",
      "first-page": "64",
      "DOI": "10.1093/annonc/mdh007",
      "article-title": "Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma",
      "volume": "15",
      "author": "Assersohn",
      "year": "2004",
      "journal-title": "Ann Oncol"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0065",
      "doi-asserted-by": "crossref",
      "first-page": "1850",
      "DOI": "10.1038/sj.bjc.6602575",
      "article-title": "Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer",
      "volume": "92",
      "author": "Kim",
      "year": "2005",
      "journal-title": "Br J Cancer"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0070",
      "first-page": "4219",
      "article-title": "Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.)",
      "volume": "23",
      "author": "Giuliani",
      "year": "2003",
      "journal-title": "Anticancer Res"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0075",
      "first-page": "2973",
      "article-title": "Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma",
      "volume": "25",
      "author": "Kunisaki",
      "year": "2005",
      "journal-title": "Anticancer Res"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0080",
      "doi-asserted-by": "crossref",
      "first-page": "499",
      "DOI": "10.1159/000087136",
      "article-title": "Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy",
      "volume": "28",
      "author": "Stahl",
      "year": "2005",
      "journal-title": "Onkologie"
    },
    {
      "issue": "2",
      "key": "10.1016/j.ejca.2011.06.002_b0085",
      "doi-asserted-by": "crossref",
      "first-page": "81",
      "DOI": "10.1016/j.clon.2004.10.006",
      "article-title": "Review of second-line chemotherapy for advanced gastric adenocarcinoma",
      "volume": "17",
      "author": "Wilson",
      "year": "2005",
      "journal-title": "Clin Oncol (R Coll Radiol)"
    },
    {
      "issue": "6",
      "key": "10.1016/j.ejca.2011.06.002_b0155",
      "doi-asserted-by": "crossref",
      "first-page": "997",
      "DOI": "10.1038/sj.bjc.6601226",
      "article-title": "Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial",
      "volume": "89",
      "author": "K\u00f6hne",
      "year": "2003",
      "journal-title": "Br J Cancer"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0095",
      "doi-asserted-by": "crossref",
      "first-page": "1450",
      "DOI": "10.1093/annonc/mdn166",
      "article-title": "Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy na\u00efve patients with advanced adenocarcinoma of the stomach or osophagogastric junction",
      "volume": "19",
      "author": "Dank",
      "year": "2008",
      "journal-title": "Ann Oncol"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0100",
      "doi-asserted-by": "crossref",
      "first-page": "4319",
      "DOI": "10.1200/JCO.2004.01.140",
      "volume": "22",
      "author": "Bouche",
      "year": "2004",
      "journal-title": "J Clin Oncol"
    },
    {
      "issue": "5",
      "key": "10.1016/j.ejca.2011.06.002_b0105",
      "doi-asserted-by": "crossref",
      "first-page": "807",
      "DOI": "10.1200/JCO.2003.08.058",
      "article-title": "Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer",
      "volume": "21",
      "author": "Fuchs",
      "year": "2003",
      "journal-title": "J Clin Oncol"
    },
    {
      "issue": "6",
      "key": "10.1016/j.ejca.2011.06.002_b0160",
      "doi-asserted-by": "crossref",
      "first-page": "1055",
      "DOI": "10.1038/sj.bjc.6602462",
      "article-title": "Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study",
      "volume": "92",
      "author": "Van Cutsem",
      "year": "2005",
      "journal-title": "Br J Cancer"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0115",
      "doi-asserted-by": "crossref",
      "first-page": "507",
      "DOI": "10.2307/2531201",
      "article-title": "Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance and stratification",
      "volume": "42",
      "author": "Lachin",
      "year": "1986",
      "journal-title": "Biometrics"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0120",
      "doi-asserted-by": "crossref",
      "first-page": "457",
      "DOI": "10.1080/01621459.1958.10501452",
      "article-title": "Nonparametric estimation from incomplete observations",
      "volume": "53",
      "author": "Kaplan",
      "year": "1958",
      "journal-title": "J Am Stat Ass"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0125",
      "first-page": "185",
      "article-title": "Asymptotically efficient rank invariation test procedures (with discussion)",
      "volume": "135",
      "author": "Peto",
      "year": "1972",
      "journal-title": "J R Stat Soc"
    },
    {
      "year": "1979",
      "series-title": "WHO Handbook for Reporting Results of Cancer Treatment, WHO Offset Publication No. 48",
      "key": "10.1016/j.ejca.2011.06.002_b0165"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0135",
      "doi-asserted-by": "crossref",
      "first-page": "18s",
      "DOI": "10.1200/jco.2010.28.18_suppl.lba4007",
      "article-title": "AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine, cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)",
      "volume": "28",
      "author": "Kang",
      "year": "2010",
      "journal-title": "J Clin Oncol"
    },
    {
      "key": "10.1016/j.ejca.2011.06.002_b0140",
      "doi-asserted-by": "crossref",
      "first-page": "1402",
      "DOI": "10.1038/sj.bjc.6604732",
      "article-title": "Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?",
      "volume": "99",
      "author": "Catalano",
      "year": "2008",
      "journal-title": "Br J Cancer"
    },
    {
      "issue": "9",
      "key": "10.1016/j.ejca.2011.06.002_b0145",
      "doi-asserted-by": "crossref",
      "first-page": "903",
      "DOI": "10.1016/S1470-2045(09)70136-6",
      "article-title": "Is there a role for second-line chemotherapy in advanced gastric cancer?",
      "volume": "10",
      "author": "Wesolowski",
      "year": "2009",
      "journal-title": "Lancet Oncol"
    }
  ],
  "container-title": "European Journal of Cancer",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "https://api.elsevier.com/content/article/PII:S0959804911003960?httpAccept=text/xml",
      "content-type": "text/xml",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://api.elsevier.com/content/article/PII:S0959804911003960?httpAccept=text/plain",
      "content-type": "text/plain",
      "content-version": "vor",
      "intended-application": "text-mining"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2019,
        6,
        12
      ]
    ],
    "date-time": "2019-06-12T22:58:07Z",
    "timestamp": 1560380287000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://linkinghub.elsevier.com/retrieve/pii/S0959804911003960"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2011,
        10
      ]
    ]
  },
  "references-count": 29,
  "journal-issue": {
    "issue": "15",
    "published-print": {
      "date-parts": [
        [
          2011,
          10
        ]
      ]
    }
  },
  "alternative-id": [
    "S0959804911003960"
  ],
  "URL": "http://dx.doi.org/10.1016/j.ejca.2011.06.002",
  "relation": {},
  "ISSN": [
    "0959-8049"
  ],
  "subject": [],
  "container-title-short": "European Journal of Cancer",
  "published": {
    "date-parts": [
      [
        2011,
        10
      ]
    ]
  }
}